Mounjaro on Medicare in North Carolina: $86 Million in 2023 and Where Costs Are Headed

by

Skyler Abilla

Mounjaro on Medicare in North Carolina: $86 Million in 2023 and Where Costs Are Headed

Mounjaro cost North Carolina Medicare $86 million in 2023, its first full year. Here is how tirzepatide is covered today, what changed in 2026, and what to check before December 7.

The Newest Diabetes Drug Costing North Carolina Medicare $86 Million in Its First Full Year

Ranked 165th in prescriptions. But Mounjaro is already NC's 18th most expensive Medicare drug after launching in mid-2022.

$85.6M
Total NC Medicare spend on Mounjaro (tirzepatide), 2023
$1,278
Average cost per prescription, 2023
#165 / #18
Rank by prescriptions / rank by total cost

What is Mounjaro and how is it different from Ozempic?

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist from Eli Lilly, approved for Type 2 diabetes in May 2022. It activates two hormone pathways instead of one, producing larger reductions in blood sugar and body weight than existing GLP-1 drugs in clinical trials. NC Medicare Part D covers it for diabetes. In 2023 it was still relatively new, which is why it ranked 165th by prescription volume but already 18th by total cost.

Why does it cost $1,278 per prescription?

Eli Lilly manufactures Mounjaro under patent and no generic exists. NC Medicare filled 66,989 Mounjaro prescriptions in 2023 for $85.6 million.

Mounjaro and Zepbound are the same drug

Tirzepatide is sold under two brand names. Mounjaro is the diabetes brand, and Zepbound is the brand for weight loss. Part D covers Mounjaro for Type 2 diabetes. For weight loss, a temporary program now exists: from July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge lets eligible Part D enrollees, in a stand-alone drug plan or a Medicare Advantage plan with drug coverage, get the KwikPen form of Zepbound, Wegovy and Foundayo for a flat $50 monthly copay. It requires prior authorization from your prescriber, it is processed separately from your Part D plan, and the $50 does not count toward your Part D deductible or out-of-pocket cap. It does not change how Mounjaro is covered for diabetes.

Where diabetes drug prices are headed

Several of the diabetes drugs that dominate North Carolina's Part D spending are moving to Medicare-negotiated prices. Mounjaro, approved in May 2022, is a newer drug, and the negotiation program applies to drugs that have been on the market for years.

Diabetes drugNegotiated price takes effect
Jardiance, FarxigaJanuary 1, 2026
Ozempic, Rybelsus, WegovyJanuary 1, 2027 ($274 for a 30-day supply)
TrulicitySelected in January 2026; any price would take effect no earlier than January 1, 2028

What Part D enrollees should know

Mounjaro's formulary placement varies widely, and prior authorization requirements are common. Compare how different plans cover Mounjaro versus Ozempic during open enrollment. If both are appropriate for your situation, the plan that tiers your specific drug lower can save hundreds of dollars a year. Part D caps what you pay out of pocket for covered drugs at $2,100 in 2026 and $2,400 in 2027, and the Medicare Prescription Payment Plan can spread your costs into monthly payments.

Check your plan before December 7

  • Open Medicare Plan Finder at Medicare.gov and enter Mounjaro with your dose and pharmacy.
  • Compare tier, prior authorization or step therapy rules, and the 2027 deductible for each plan.
  • If you already have a plan, read its 2027 Annual Notice of Change.

For the bigger 2027 picture, read our guide to Medicare Part D in 2027.

Talk to a local agent

Skyler Abilla is a licensed Medicare agent serving North Carolina and South Carolina. Bring your medication list and we will check each drug against every plan available at your address. Call (843) 284-6815 or book a free call.

NC Medicare spent $85.6 million on Mounjaro in 2023, its first full year of availability. Ozempic, which launched earlier in the same class, cost $407 million that year.
Top 10 North Carolina Drugs by Total Medicare Part D Spending, 2023

Source: CMS Medicare Part D Prescribers by Geography and Drug, 2023 (North Carolina). Negotiated prices and drug lists: CMS Medicare Drug Price Negotiation Program, as reported by NBC News (November 2025) and CMS (January 27, 2026). GLP-1 Bridge: CMS program details as summarized by NFP (June 10, 2026). Part D 2026 and 2027 cap: CMS CY 2027 Rate Announcement (April 2026). Mounjaro is not in the top ten shown below; the chart shows the leading drugs for comparison.

A note on this data: Spending figures come from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescribers by Geography & Drug dataset, 2023. This data covers Medicare Part D only and does not represent commercial insurance, Medicaid, or cash-pay prescriptions. Suppressed values (fewer than 11 beneficiaries) are excluded from totals.

This article is for educational purposes only. Nothing here is medical advice. Talk to your doctor before making any decisions about your medications or treatment. Abilla Advisors does not offer every plan available in your area. For information on all of your options, contact Medicare.gov, 1-800-MEDICARE, or your State Health Insurance Assistance Program (SHIP). This content is not connected with or endorsed by the U.S. Government or the federal Medicare program.

Get a free Medicare plan comparison

Tell us a little about you and a licensed Abilla Advisors agent will call you. No cost, no obligation.

Thank you. Your request was received and a licensed agent will call you soon.
Something went wrong. Please call us at (843) 284-6815.

We do not offer every plan available in your area. To get information on all of your options, contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Assistance Program (SHIP).

Related articles

Get Help – No Cost to You

Get personalized Medicare guidance with no cost and no obligation.